A study to understand the effect of anti-acne medication and overall improvement in patients with severe acne.
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: L700- Acne vulgaris
- Registration Number
- CTRI/2024/07/070813
- Lead Sponsor
- Sun Pharmaceutical Industries Ltd. (SPIL)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Male or female greater than equal to 12 years of age
2. Patients diagnosed with severe recalcitrant nodular facial acne by treating dermatologist
3. Patient who completed at least 8 weeks of therapy with low dose micronized-isotretinoin (Sotret® NF)
Exclusion Criteria
1. Pregnant and lactating females
2. Patient who had already taken conventional or micronized isotretinoin in the past
3. Known hypersensitivity to isotretinoin
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in severity of acne based on Investigator’s Global Assessment (IGA) scale (score 0-4) from baseline to 8 weeks of treatmentTimepoint: Baseline to 8 weeks
- Secondary Outcome Measures
Name Time Method